Skip to main content
SpringerLink
Log in

Foreword

  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Management of stable angina pectoris: recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 1997; 18: 394–413

    Article  Google Scholar 

  2. Epstein SE, Beiser GD, Goldstein RE, et al. Treatment of angina pectoris by electrical stimulation of the carotid-sinus nerves. N Eng J Med 1969; 280: 971–8

    Article  CAS  Google Scholar 

  3. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol 1986; 57: 43–49F

    Article  Google Scholar 

  4. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J Suppl 1999; 1 Suppl. H: H64–69

    Google Scholar 

  5. Levy RL, White PD, Stroud WD, et al. Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA 1945; 129: 585–8

    Article  Google Scholar 

  6. Palatini P. Heart rate as an independent risk factor for cardiovascular disease: current evidence and basic mechanisms. Drugs 2007; 67 Suppl. 2: 3–13

    Article  PubMed  Google Scholar 

  7. Borer JS, Fox K, Jaillon P, et al. Anti-anginal and anti-ischemic effects of ivabradine, an If inhibitor, in stable angina: a randomized, double-blinded, multicentered, placebo-controlled trial. Circulation 2003; 107: 817–23

    Article  PubMed  Google Scholar 

  8. DiFrancesco D, Borer JS. The funny current: cellular basis for the control of heart rate. Drugs 2007; 67 Suppl. 2: 15–24

    Article  PubMed  Google Scholar 

  9. Berdeaux A. Preclinical results with If current inhibition by ivabradine. Drugs 2007; 67 Suppl. 2: 25–33

    Article  PubMed  Google Scholar 

  10. Tardif J-C. Clinical results of If current inhibition by ivabradine. Drugs 2007; 67 Suppl. 2: 35–41

    Article  PubMed  Google Scholar 

  11. Böhm M, Reil J-C. Perspectives of If inhibition by ivabradine in cardiology. Drugs 2007; 67 Suppl. 2: 43–9

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Professor Borer is a paid consultant to Servier Laboratoires, the manufacturer of ivabradine.

Author information

Authors and Affiliations

  1. New York Presbyterian Hospital-Weill Cornell Center, New York, New York, USA

    Jeffrey S. Borer

Authors
  1. Jeffrey S. Borer
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Borer, J.S. Foreword. Drugs 67 (Suppl 2), 1–2 (2007). https://doi.org/10.2165/00003495-200767002-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767002-00001

Search

Navigation